Septerna (SEPN) to Release Earnings on Thursday

Septerna (NASDAQ:SEPN) is expected to be announcing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $15.5570 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The business had revenue of $24.12 million for the quarter, compared to analyst estimates of $20.44 million. Septerna had a negative return on equity of 15.85% and a negative net margin of 106.37%. On average, analysts expect Septerna to post $-7 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Septerna Stock Down 1.7%

SEPN opened at $23.78 on Tuesday. The firm has a market capitalization of $1.07 billion, a P/E ratio of -21.42 and a beta of 3.43. The stock’s 50 day moving average price is $26.62 and its two-hundred day moving average price is $24.03. Septerna has a 12-month low of $4.66 and a 12-month high of $32.63.

Wall Street Analyst Weigh In

SEPN has been the subject of several research reports. Zacks Research raised Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Thursday, January 22nd. Truist Financial upped their target price on shares of Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. JonesTrading initiated coverage on shares of Septerna in a report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 price target for the company. Finally, HC Wainwright raised their price target on shares of Septerna from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Insider Buying and Selling

In other news, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total transaction of $115,880.00. Following the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. This trade represents a 2.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samira Shaikhly sold 70,453 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total value of $1,979,729.30. Following the sale, the insider owned 793 shares in the company, valued at approximately $22,283.30. This represents a 98.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Septerna

Institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in shares of Septerna during the 4th quarter worth about $650,000. VARCOV Co. bought a new stake in Septerna in the fourth quarter valued at about $631,000. Virtus Investment Advisers LLC acquired a new position in Septerna in the fourth quarter worth about $292,000. Tudor Investment Corp ET AL acquired a new position in Septerna in the fourth quarter worth about $503,000. Finally, Numerai GP LLC bought a new position in Septerna during the fourth quarter worth about $1,279,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.